Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer
Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer
复制标题
DOI：
10.3233/cbm-150472
复制
发表时间：
2015-01-01
影响因子：
3.1
通讯作者：
Ogawa, Osamu
中科院分区：
文献类型：
--
作者：
Nakashima, Masakazu;Matsui, Yoshiyuki;Ogawa, Osamu
背景和目的：阐明尿液趋化因子（C-X-C基序）配体1（CXCL1）作为膀胱癌（BCa）患者肿瘤检测和预后预测的生物标志物的临床用途和诊断准确性。方法：我们测量了175名BCa患者和30名健康对照者的尿液CXCL1水平。通过尿肌酐标准化的尿液 CXCL1 浓度 (CXCL1/Cre) 的值在检测膀胱肿瘤和预测经尿道切除 (TUR) 后膀胱内复发方面进行了分析。结果：BCa 患者中的 CXCL1/Cre 显着高于健康参与者（3 倍），并且晚期 BCa 患者与对照样本的差异更大。尽管尿细胞学检测通常对低度浅表肿瘤患者失去诊断能力，但 CXCL1/Cre 的敏感性在该患者群体中并未受到影响。 CXCL1/Cre 较高的患者在 TUR 后发生膀胱内复发的可能性明显更高，多变量分析确定 CXCL1/Cre 是 TUR 后膀胱内复发的独立预测因子。重要的是，CXCL1/Cre 可以根据 EORTC 风险标准成功地将中危患者 TUR 后复发的概率分为相当于高危组和低危组的两组。结论：尿液 CXCL1 是一种有前景的非侵入性分子标记物，可用于 BCa 患者的肿瘤检测和结果预测。
BACKGROUND AND OBJECTIVE: To clarify the clinical usefulness and diagnostic accuracy of urine chemokine (C-X-C motif) ligand 1 (CXCL1) as a biomarker for tumor detection and outcome prediction in patients with bladder cancer (BCa).METHODS: We measured urine CXCL1 levels in 175 patients with BCa and 30 healthy controls. The value of urine CXCL1 concentration normalized by urine creatinine (CXCL1/Cre) was analyzed in terms of detecting bladder tumors and predicting intravesical recurrence after transurethral resection (TUR).RESULTS: CXCL1/Cre was significantly higher (3-fold) in BCa patients than in healthy participants and the difference from control samples was greater in patients with advanced BCa. Although the urine cytology test generally lost diagnostic power in patients with low-grade superficial tumors, the sensitivity of CXCL1/Cre was not compromised in this patient population. Patients with higher CXCL1/Cre were significantly more likely to develop intravesical recurrence after TUR and multivariate analysis identified CXCL1/Cre as an independent predictor of post-TUR intravesical recurrence. Importantly, CXCL1/Cre could successfully classify the probabilities of post-TUR recurrence among patients with intermediate-risk according to EORTC risk criteria into two groups equivalent to its high- and low-risk groups.CONCLUSIONS: Urine CXCL1 is a promising, non-invasive molecular marker for tumor detection and outcome prediction in patients with BCa.